Share >  
Share
Share on Tumblr

Rheoscience

News »

   latest by relevance
Dr Reddy's says diabetic drug trial successful
Jan 05, 2010 at 08:29 | Source: Reuters
Drugmaker Dr Reddy's Laboratories said on Monday phase III clinical trial for its anti-diabetic molecule balaglitazone, being conducted by Danish firm Rheoscience, had achieved the set parameters.
Dr Reddys new diabetic drug to hit market in 2011
Nov 16, 2007 at 08:30 | Source: Business Line
Balaglitazone, a new diabetic drug candidate of Dr Reddys Laboratories, is currently undergoing phase III clinical trails and will hit the market by 2011, according to Mr K. Anji Reddy, Founder-Chairman, Dr Reddys Laboratories Ltd.
Dr Reddys & Rheoscience commence trial of Balaglitazone
Aug 02, 2007 at 16:05
Dr Reddys and Rheoscience commence the first Phase III trial of Balaglitazone (DRF 2593). Balaglitazone is a novel TZD candidate for the treatment of diabetes mellitus
Diabetes drug: Dr Reddys, Danish co start phase III trials
Aug 02, 2007 at 08:36
Dr Reddys Laboratories and the Danish biopharmaceutical company Rheoscience today announced the commencement of the first phase III trial of Balaglitazone (DRF 2593), a potential drug for diabetes.
Dr Reddy's diabetes molecule likely to enter phase-III soon
Sep 21, 2006 at 08:45
Dr Reddy's Laboratories Ltd, which has lined up seven new chemical entities in its drug discovery fold, is hopeful of its most promising diabetes molecule DRF-2593 (Balaglitazone) to enter the phase-III clinical trials soon.
Dr Reddy's re-focusing on research
Aug 24, 2006 at 21:15
Dr Reddy's is stepping-up work in its research shop. The company has even put the development of its 'Red Heart Pill' on the fast track, reports CNCB-TV18.

Photos »

  /  

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window